Clinical trials: Age Related Macular Degeneration
Macular Edema, Retinal Vein Occlusion
Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®
This study will use retrospective data to evaluate the safety and efficacy of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) in the treatment of macular oedema due to retinal vein occlusion (RVO) in clinical practice.
- Trial name
- NCT02181530
- Testing
- No Intervention
- Where
- Poland
- Volunteers
- 43 people
- Sponsor
- Allergan
Age-Related Macular Degeneration
A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration
The purpose of the study is to evaluate the safety and efficacy of intravitreal (IVT) administration of DE-120 in subjects with treatment-naive active subfoveal choroidal neovascularization (CNV) secondary to age-related macular…
- Trial name
- VAPOR1 (NCT02401945)
- Testing
- DE-120, Aflibercept
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Santen Inc.
Diabetic Macular Edema
Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)
This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.
- Trial name
- NCT00536692
- Testing
- mecamylamine
- Where
- 3 sites in United States
- Sponsor
- CoMentis
Neovascular Wet Age-related Macular Degeneration (AMD)
Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
The primary objective of the study is to investigate the safety of intravitreal (IVT) REGN2176-3 in patients with neovascular wet age-related macular degeneration (AMD).
- Trial name
- NCT02061865
- Testing
- REGN2176-3
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Regeneron Pharmaceuticals
Exudative Macular Degeneration
Pilot Study of X-82 in Patients With Wet AMD
The objective of this study is to evaluate the safety and preliminary biologic activity/efficacy of X-82 in patients with wet Age-related Macular Degeneration (AMD).
- Trial name
- NCT01674569
- Testing
- X-82 oral, ranibizumab (Lucentis)
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tyrogenex
Non-exudative (Dry) Age-related Macular Degeneration (AMD)
HELP Therapy for Dry AMD
This is an open-label, single center clinical investigation to evaluate the efficacy and safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a treatment for non-exudative (dry) Age-related…
- Trial name
- HELPuc (NCT01840683)
- Testing
- H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- B.Braun Avitum AG
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Macular Edema, Branch Retinal Vein Occlusion
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at…
- Trial name
- BALATON (NCT04740905)
- Testing
- Faricimab, Aflibercept
- Where
- 150 sites in United States, Argentina and 20 more
- Volunteers
- 553 people
- Sponsor
- Hoffmann-La Roche
Geographic Atrophy
Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD
The objective of this study is to evaluate the efficacy and safety of the PRIMA System in patients with atrophic AMD. Eligible subjects will be implanted with the PRIMA Implant.
- Trial name
- PRIMAvera (NCT04676854)
- Testing
- PRIMA Bionic Vision System
- Where
- 21 sites in France, Germany and 4 more
- Volunteers
- 38 people
- Sponsor
- Science Corporation
Wet Age-related Macular Degeneration
A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)
This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of JL14002 compared to Lucentis® in subjects with wAMD.
- Trial name
- NCT07389577
- Testing
- JL14002 monoclonal antibody(Fixed dosing regimen), Ranibizumab(Fixed dosing regimen), JL14002 monoclonal antibody(PRN)
- Where
- China
- Volunteers
- 443 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Intermediate AMD
A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD
The proposed clinical investigation wants primary to validate the safety of the innovative light therapy approach and in second priority provide insight and confirmations on therapeutic effect.
- Trial name
- retinaSEES-PoC (NCT06557369)
- Testing
- reSEES
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Oculox Technologies SA
Dry Age-related Macular Degeneration
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
The purpose of this clinical study was to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration…
- Trial name
- NCT04566445
- Testing
- GT005
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 255 people
- Sponsor
- Gyroscope Therapeutics Limited
Neovascular Age-related Macular Degeneration
Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice
BESRA is a national, multi-center, prospective, observational study to assess the effectiveness of brolucizumab intravitreal injections in patients with nAMD treated in the UK.
- Trial name
- BESRA (NCT05112835)
- Testing
- brolucizumab
- Where
- 17 sites in United Kingdom
- Volunteers
- 302 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
This is a study in adults with geographic atrophy, an advanced form of age-related macular degeneration. The purpose of this study is to find out how well different doses of BI 754132 are tolerated.
- Trial name
- NCT04002310
- Testing
- BI 754132
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Boehringer Ingelheim
Age-Related Maculopathy, Age-Related Maculopathies
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
The purpose of this study is to determine the safety and tolerability of multiple doses of RN6G in subjects with advanced dry, age-related macular degeneration including geographic atrophy.
- Conditions
- Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration
- Trial name
- NCT01003691
- Testing
- RN6G
- Where
- 24 sites in United States
- Volunteers
- 24 people
- Sponsor
- Pfizer
Age-Related Macular Degeneration
Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD
To evaluate the safety of 3 regimens of short-term, low-dose systemic IMT as rejection prophylaxis prior to and/or following transplant of MA09-hRPE cells.
- Trial name
- PORTRAY (NCT02563782)
- Testing
- Sub-retinal transplantation of MA09-hRPE cells, tacrolimus and mycophenolate mofetil
- Where
- United States
- Sponsor
- Astellas Institute for Regenerative Medicine
Macular Edema, Central Retinal Vein Occlusion
Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion
This study evaluates the efficacy and safety of Conbercept ophthalmic injection. This is a multi-center, randomized, double-masked, placebo-controlled phase III clinical study.
- Trial name
- CRAVE (NCT03223714)
- Testing
- Conbercept Ophthalmic Injection
- Where
- 27 sites in China
- Volunteers
- 242 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Neovascular Age-related Macular Degeneration
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
A Phase I/IIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration
- Trial name
- NCT06141460
- Testing
- RRG001
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Refreshgene Technology Co., Ltd.
Geographic Atrophy, Age-Related Macular Degeneration
Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
The purpose of this study is to characterize emixustat hydrochloride pharmacokinetic and pharmacodynamic parameters in subjects with geographic atrophy associated with dry age-related macular degeneration.
- Trial name
- NCT02130531
- Testing
- Emixustat HCl Tablet
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Kubota Vision Inc.
Age-related Macular Degeneration, Diabetic Macular Edema
Observational Study of Vision Improvement in Patients With Retinal Disorders
The purpose of this study is to assess the vision improvement achieved by patients with retinal disorders who received corneal treatments by a low vision aid device.
- Trial name
- NCT04693702
- Testing
- Corneal treatment by a low vision aid device
- Where
- Canada
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Optimal Acuity Corporation